Review

Impact of fatty diets on blood pressure: A systematic review and meta-analysis

Tingzhen Zang MS¹, Waseem Hassan PhD², Faraza Javaid PhD³, Ramla Shabbir PhD⁴, Andleeb Shahzadi PhD⁵, Hammad Ahmed PhD⁶

¹Department of Internal Medicine, Tsinghua University Hospital, Beijing, China ²Department of Pharmacy, COMSATS University Islamabad, Lahore campus, Lahore, Pakistan ³College of Pharmacy, Quiad-e-Azam educational complex, Sahiwal, Pakistan ⁴Department of Pharmacy, The University of Lahore, Lahore, Pakistan ⁵Department of Medical Pharmacology, Cerrahpasa, Istanbul University, Turkey ⁶Department of Pharmacy, Sialkot institute of Science and Technology, Sialkot, Pakistan

Background and Objectives: Hypertension is a major risk factor for cardiovascular diseases, with dietary fats playing a critical role in its regulation. While unsaturated fats are associated with blood pressure (BP) reduction, saturated and trans fats may exacerbate hypertension. This systematic review and meta-analysis aimed to evaluate the impact of various fatty diets on systolic (SBP) and diastolic blood pressure (DBP) and identify dietary patterns most effective for BP management. Methods and Study Design: A comprehensive search of MEDLINE and ClinicalTrials.gov (inception to February 2025) identified randomized clinical trials and observational studies assessing dietary fats' effects on BP. Twenty-five studies (n=14,522 participants) met inclusion criteria. Data were analyzed to estimate mean differences (MDs) with 95% confidence intervals (CIs). Funnel plots were generated to assess publication bias. Risk of bias was assessed using the RevMan Web tool, and sensitivity analyses were conducted. Results: Food-based oil diets significantly reduced SBP and DBP (MD: -18.43 and -12.90 mm Hg). Low-fat and unsaturated fat-enriched diets lowered SBP (-6.91 and -4.46 mm Hg) and DBP (-3.78 and -0.74 mm Hg). The DASH diet had moderate effects (SBP: -3.83, DBP: -2.18 mm Hg). Omega-3 and high-fat diets showed smaller reductions. Saturated fat restriction had minimal impact. Conclusions: Food-based fatty oil diets had the greatest BP reduction, while low-fat, unsaturated fat-enriched, and DASH diets (fat-based variation) showed moderate effects. High-fat and omega-3 diets had smaller impacts, emphasizing diet's role in BP management.

Key Words: hypertension, fatty diets, systolic blood pressure (SBP), diastolic blood pressure (DBP), unsaturated fats

INTRODUCTION

Dietary fats play a crucial role in influencing blood pressure (BP) levels in individuals. A fatty diet refers to a dietary pattern characterized by a high intake of fats, including saturated fats, monounsaturated fats (MUFA), and polyunsaturated fats (PUFA). These diets can vary based on fat type and source, such as animal fats, plantbased oils, or omega-3 fatty acids.Research suggests that specific components of dietary fats, such as marine n-3 polyunsaturated fatty acids (PUFAs), have been associated with significant BP-lowering effects, particularly in hypertensive populations.^{1,2} Conversely, the impact of other dietary fatty acids on BP remains inconclusive, with inconsistent or minor clinical effects noted.³ Additionally, studies have shown that dietary fats obtained from seafood and dairy products can potentially protect against abnormal BP, highlighting the importance of the fat source in BP management.⁴ Furthermore, the oxidation of omega-6 fats like linoleic acid can lead to the production of reactive aldehydes that inhibit nitric oxide generation, potentially elevating BP levels and contributing to hypertension.⁵ Understanding the diverse effects of different dietary fats on BP regulation are essential for developing effective dietary recommendations for hypertension prevention and management.

Different types of dietary fats have varying effects on BP. Research suggests that marine PUFAs have a notable BP lowering effect, especially in hypertensive populations, while the Dietary Approaches to Stop Hypertension (DASH) diet and Mediterranean-style diet, which are lower in saturated fatty acids, and higher in monounsaturated fats (MUFAs), are beneficial for hypertension prevention and management.⁶ Conversely, high intake of saturated fatty acids, MUFAs, and trans-unsaturated fatty

Corresponding Author: Dr Waseem Hassan, Department of Pharmacy, COMSATS University Islamabad, Lahore Campus, Defence Road, Off Raiwind Road, Lahore 54000, Punjab, Pakistan

Tel: +923317098808

Email: waseemhassan@cuilahore.edu.pk

Manuscript received 19 December 2024. Initial review completed 12 January 2025. Revision accepted 09 April 2025. doi: 10.6133/apjcn.202508_34(4).0005 acids has been associated with an increased risk of hypertension, with trans fatty acidsshowing a significant positive association even after adjusting for obesity-related factors.⁷ Additionally, PUFAs, including omega-3 and omega-6 PUFAs, did not show a significant association with hypertension risk in middle-aged and older women.8 Therefore, incorporating sources of beneficial fats like marine n–3 PUFAs, MUFAs, and avoiding high saturated fatty acids and trans fatty acidsmay play a crucial role in BP regulation.

Previous studies have extensively investigated the effects of different dietary fats on BP. Replacing saturated fatty acids with unsaturated fats, particularly MUFAs, has been linked to beneficial effects on cardiometabolic profiles, such as increased HDL cholesterol and reduced aspartate aminotransferase levels.⁹ Moreover, high-MUFA diets, when substituted for high-carbohydrate diets, did not demonstrate a greater reduction in BP in individuals with and without hypertension.¹⁰ Furthermore, higher circulatory/dietary n-6 PUFAs have been associated with a lower risk of hypertension, particularly total n-6 PUFAs and linoleic acid.¹⁰ These findings collectively emphasize the importance of considering the quality and type of dietary fats in managing BP.

Though sufficient literature exists on the effects of fatty diets on BP, it is unknown to what extent they are effective in clinical settings. The comparisons of different fatty diets and their effects on BP would greatly be helpful in understanding their role and extent of effects on systolic blood pressure (SBP) and diastolic blood pressure (DBP). This systematic review and meta-analysis aims to highlight the available literature from clinical trials and Randomized Controlled Trials (RCTs) that demonstrate the effectiveness and extent to which fatty diets can regulate blood pressure in clinical settings. Specifically, the research question is: How do different types of high-fat diets influence SBP and DBP among individuals with any BP, regardless of age and gender? PICO framework is provided in Table 1.

METHODS

Design

This systematic review and meta-analysis followed the Cochrane Handbook for Systematic Reviews of Intervention.11 Results were reported in accordance with the Preferred Reporting Items for SystematicReviews and Meta-Analyses (PRISMA) guidelines¹² (Supplementary Table 1). The review protocol is registered with PRSOPERO (registration number: CRD42024546244). This article is a review of previously published literature and does not involve any studies with human participants or animals performed by the authors. Therefore, ethical approval was not required. Search strategy

MEDLINE and Clinicaltrials.gov was searched before February 19, 2025, using criteria based on PICOS (Table 1), except that study design (S) was applied during the screening stage rather than in the initial search strategy. Manual search of references of the included studies supplemented the electronic search. However, no additional relevant studies were identified through this process. RCTs and clinical trials were identified using the relevant search terms. Search strategies for MEDLINE and Clinicaltrials.gov are provided in Supplementary Table 2 and Supplementary Table 3 respectively.

Study selection and inclusion/exclusion criteria

To conduct a systematic review and meta-analysis on the potential effects of different types of fatty diets in hypertensive and normotensive individuals, rigorous inclusion and exclusion criteria were established. The inclusion criteria were clearly defined to ensure the relevance and focus of the study. Included studies must involve hypertensive patients or individuals with any BP levels consuming any type of fatty diet (or where the major content of the diet is fat-based), without restrictions on age and gender groups. Only randomized controlled trials (RCTs) and clinical studies were considered for inclusion. Only dietary fat intake from whole foods was considered. The search was kept limited to articles indexed in MEDLINE and ClinicalTrials.gov.

To ensure consistency and minimize confounding factors, specific exclusion criteria were applied. Exclusion criteria encompass studies involving hypertensive patients with concurrent diseases such as diabetes, hyperlipidemia, or metabolic syndrome. Articles that do not administer a fatty diet as an intervention, lack full-text availability, are not in English, or fully restrict the fatty diet rather than administering it as an intervention were also excluded. Fatty diets consumed through capsules or tablets (e.g., supplements) were excluded. Furthermore, review articles, animal studies, and *in-vitro* studies were also excluded from the analysis.

Additional exclusion measures were implemented to improve study quality and focus on primary dietary effects. No upper limit for hypertension and no lower limit for hypotension (as a result of interventions) were considered in the selection criteria of studies. Studies with previous or current anti-hypertensive medication use were excluded to eliminate potential confounding effects of pharmacological interventions. Studies without clear baseline BP measurements or lacking quantifiable effect values for outcomes were also excluded. The studies with baseline data before the diet intervention were considered as control, while the studies with isolated control and intervention groups were considered as detailed in

Table	1.	PI	C	ЭS
I GOIC			~	-

Criteria	Description
Participant(s)	Individuals with any blood pressure without restrictions on age and gender
Intervention(s)	Any type of fatty diets
Comparison(s)	Comparison between types of high-fat diets
Outcome(s)	SBP and DBP
Study design	RCTs and clinical trials

Supplementary Table 4.

Data extraction

Data extraction was performed by two impartial reviewers using a standard proforma. Firstly, every article was entered into Endnote in order to compile research and remove duplicates. After examining the titles and abstracts, papers that did not fit the eligibility requirements were subsequently eliminated. Further, articles from which effect values could not be collected or access was restricted were omitted. The meta-analysis was finally performed on the articles that met the requirements. Relevant data included information on study authorship, publication year, study design, duration, type of fatty diet used, number of patients, age (years), gender distribution, SBP (mm Hg), DBP (mm Hg), methods used for BP measurements, study duration, BP measurement frequency during study will be extracted.

Mean differences (MDs) in end-of-treatment SBP and DBP were the main results. Review Manager, v5.3 (The Nordic Cochrane Centre, The Cochrane Collaboration, Copenhagen, Denmark) was used to analyse the data. The MDs were determined by deducting the administered fatty diet group's end-of-treatment SBP and DBP values from either the control diet group's end-of-treatment values or the pre-treatment SBP and DBP values.

The 95% CIs for the MDs were presented. A fixedeffects model was used to compare the results after the MDs \pm SE (MD) from each research were combined and analyzed using the general inverse variance method with random effects model.^{11,13} For MD comparisons, a 2sided *p* <0.05 was used as the threshold of significance. All crossover study data were subjected to paired analysis.¹⁴ When data were unavailable, authors were contacted, and studies were considered irretrievable if no answer was received after three attempts.¹⁵

Risk of bias assessment

Using the RevMan Web Risk of Bias Assessment tool, two independent reviewers evaluated each study for bias. Sequence generation, allocation concealment, blinding, outcome data, and reporting were among the assessment domains.¹¹ Trials were classified as "unclear risk" if insufficient information was provided to identify the danger, "low risk" if methodological problems were thought to be insignificant, and "high risk" if they had flaws that could have affected the results. Disputes were settled by agreement.

Publication bias and sensitivity analysis

Publication bias and sensitivity analysis were assessed using RevMan Web tool. p<0.05 was regarded as evidence of small-study effects. Publication bias was quantitatively tested using the Egger's and Begg's tests and visually examined using funnel plots. Sensitivity tests were carried out, whereby each trial was eliminated from the meta-analysis and the effect size was recalculated using the remaining trials, in order to ascertain whether any one trial had a particularly significant impact on the overall results. Additionally, sensitivity assessments were conducted using leave-one-out technique16in Open metanalyst software.

Statistical analysis

We assessed heterogeneity among the included studies using the I² statistic and presented the data as standardized mean differences (SMDs) and 95% confidence intervals (CIs). Fixed-effects models were applied throughout the analysis, as this approach assumes a common effect size across studies and provides more precise estimates when heterogeneity is minimal.¹⁷ A sensitivity analysis was performed to evaluate the stability of the results. Begg's and Egger's tests were used to detect publication bias. p < 0.05 was set as the significance level. Data analysis was performed using RevMan Web.¹⁸

RESULTS

Study selection

A total of 25518 articles were found through search strategy (Supplementary Table 2 and Supplementary Table 3) in MEDLINE and clinicaltrials.gov databases. The selection process is detailed in the PRISMA flowchart (Figure 1). After careful screening of titles and abstracts of these articles by two independent researchers, 3157 articles were selected for a comprehensive full-text review. A total of 3,132 articles were excluded after full-text assessment due to not meeting eligibility criteria. The most common reasons for exclusion included irrelevant study methodology, administration of diets other than fatty diets, and absence of blood pressure measurement as a study parameter. After this rigorous screening process, 25 articles met the inclusion/exclusion criteria and were selected for assessment.

Characteristics of the included studies

The characteristics of the included trials are summarized in Supplementary Table 4.¹⁹⁻⁴³ The analysis was based on 25 trials selected according to predefined inclusion and exclusion criteria. Among these, 19 trials were explicitly described as RCTs, while two each were categorized as clinical trials, crossover control trials, and observational studies. A total of 14,522 participants were included across the studies, with sample sizes ranging from 12 to 12,279 individuals. The age of participants varied widely, from as young as 8 months to 75 years, with both genders well represented across the trials. Both SBP and DBP were assessed as outcomes in 24 trials, whereas one trial measured only SBP. Most studies utilized automated devices for BP measurement, while three studies used mercury sphygmomanometers.

The interventions involved various dietary modifications focused on fat intake. Two studies implemented High-Fat Diets, while six studies administered Omega-3 Fatty Acid Diets. Two studies investigated the effects of Food-Based Oil Diets, while five examined Saturated Fat Restriction Diets. Three studies administered DASH Diets (fat-based variation of the DASH diet), and six studies involved Unsaturated Fat-Enriched Diets (MUFA/PUFAenriched diets), while three studies involved Low-Fat Diets. Study durations ranged from 3 weeks to 15.8 years, with BP measurement frequencies varying from daily assessments to annual evaluations, depending on the trial design and intervention period.




Figure 1. PRISMA flowchart depicting the study selection process, outlining the number of studies identified, screened, and included in the systematic review and meta-analysis.

Effect on SBP and DBP

Figure 2 and Figure 3 depict the effects of various dietary interventions on SBP and DBP, respectively. The foodbased oil diet, specifically the sesame oil blend,³⁸ exhibited the most substantial reductions in both SBP and DBP, with MD of -21.40 mm Hg [-25.27, -17.75] and -14.00 mm Hg [-15.53, -12.47], respectively. Diets rich in unsaturated fats²⁸ also demonstrated significant reductions in SBP (-15.80 mm Hg [-18.59, -13.01]). High MUFA⁴⁴ intake and long-chain omega-3 polyunsaturated fatty acids (LC n-3 PUFA)⁴¹ markedly reduced SBP by -7.00 mm Hg [-8.41, -5.59] and -7.60 mm Hg [-13.63, -1.57], respectively, with corresponding reductions in DBP of -6.00 mm Hg [-7.52, -4.48] and -2.70 mm Hg [-6.43, -1.03]. Low-fat diets19,27,30 were associated with moderate decreases in SBP (-6.91 mm Hg [-8.44, -5.39]) and DBP (-3.78 mm Hg [-4.64, -2.91]). Similarly, the DASH diet rich in fat contents^{21,33,45} exhibited modest reductions in SBP (-3.83 mm Hg [-4.19, -3.47]) and DBP (-2.18 mm Hg [-2.41, -1.96]). In comparison, diets high in omega-3 content^{35,36,39,43,46} and overall high-fat intake^{27,32} yielded

smaller reductions in both SBP and DBP. Restriction of saturated fat intake^{22,24-26} had minimal effects on BP parameters when compared to control groups.

Sensitivity analyses

Systematic removal of individual trials did not alter the results. Sensitivity analyses using leave-one-out forest plot shows that no one study was responsible for these findings when each trial was systematically excluded from analysis. This represented a pattern of overall combined association between the administration of fatty diets and SBP and DBP (Supplementary Figure 1 (A &B)).

Risk of bias

Using the Cochrane Risk of Bias Tool (Supplementary Figure 2 (A & B)), individual trials were judged as having a high, low, or unclear risk of bias for the domains measured. Trials were judged in (A) Random sequence generation (selection bias) (B) Allocation concealment (selection bias) (C) Blinding of participants and personnel (performance bias) (D) Blinding of outcome assessment

tudy or Subgroup	Fat-based die Mean	····, ·····	ention Total	Control gro Mean	sD SD		Weight	Mean difference IV, Fixed, 95% Cl	Mean difference IV, Fixed, 95% Cl	Risk of Bias A B C D E F
.1.1 High-Fat Diets 1% fat cheddar cheese-with GABA (Maryka et al.)	134.3	11.1	49	135.5	11.2	53	0.1%	-1.20 [-5.53 , 3.13]	_	
take of high-fat diet (Straznicky et al.)	129	13	14	131	11	14	0.0%	-2.00 [-10.92 , 6.92]		
ubtotal			63			67	0.1%	-1.35 [-5.25 , 2.54]	•	
est for overall effect: Z = 0.68 (P = 0.50)									-	
eterogeneity: Chi ² = 0.03, df = 1 (P = 0.87); l ² = 0%										
1.2 Omega-3 Fatty Acid Diets										
axseed oil (Dorien J. Pieters et al.)	139.2	9.2	29	138.5	14.5	30	0.1%	0.70 [-5.48 , 6.88]		
C n-3 PUFA (Kolbrun Sveinsdottir et al.)	122.4	13.4	38	130	13.4	38	0.1%	-7.60 [-13.63 , -1.57]		• • • • • • ?
C ω-3 fatty acids (EPA & DHA)(Skilton et al.)	101.3	9.7	352	106.2	1.4	352	1.9%	-4.90 [-5.92 , -3.88]	-	
mega-3 fatty acid (Chisa Matsumoto et al.)	121.2	8.3	12279	121.3	8.5	12279	44.0%	-0.10 [-0.31 , 0.11]		
mega-3 fatty acids (Anahita Izadi et al.)	102.34	0.91	60	106.02	0.31	60	32.8%	-3.68 [-3.92 , -3.44]	-	
mega-3-PUFA (Alice V. Stanton et al.) ubtotal	115.2	14.6	39 12797	120.3	11.2	42 12801	0.1% 78.9%	-5.10 [-10.80 , 0.60]		
est for overall effect: Z = 21.38 (P < 0.00001)			12/9/			12801	/8.9%	-1.71 [-1.87 , -1.55]	1	
eterogeneity: $Chi^2 = 520.37$, $df = 5$ (P < 0.00001); I ²	= 99%									
.3 Food-Based Oil Diets										
conut Oil-Based HFD (Kay-Tee Khaw. et al.)	131.58	18.8	29	131.4	18.8	29	0.0%	0.18 [-9.50 , 9.86]		• ? • • ? •
same Oil Blend (Sankar Devarajan et al.)	143.2	10	100	164.6	17	100	0.1%	-21.40 [-25.27 , -17.53]		• ? • • •
btotal			129			129	0.2%	-18.43 [-22.02 , -14.84]	◆	
st for overall effect: Z = 10.06 (P < 0.00001) terogeneity: Chi ^z = 16.48, df = 1 (P < 0.0001); i ^z = 1	94%									
.4 Saturated Fat Restriction Diets duced intake of saturated fats (Lin et al.)	131.1	17.9	140	132.2	15	140	0.1%	-1.10 [-4.97 , 2.77]		
placement diet (SF \rightarrow UFA) (Nupponen et al.)	121.1	11.8	140	121.9	14.8	226	0.1%	-0.80 [-3.38 , 1.78]		
striction of saturated fats (Jula et al.)	134.45	12.6	47	134.84	14.6	44	0.3%	-0.39 [-5.16 , 4.38]		
striction of saturated fats (Niinikoski et al.)	117.2	11.6	248	118.4	12.1	276	0.5%	-1.20 [-3.23 , 0.83]		
turated fat with low PUFA content (Puska et al.)	124	12.8	41	128	12.8	41	0.1%	-4.00 [-9.54 , 1.54]		
btotal	124	12.0	657	120	12.0	727	1.0%	-1.18 [-2.55 , 0.19]	•	•••••
st for overall effect: Z = 1.69 (P = 0.09)									1	
eterogeneity: Chi ² = 1.19, df = 4 (P = 0.88); l ² = 0%										
1.5 DASH Diets (Fat-based variations of the DAS				100						
SH (K. E. Harnden et al.)	117.4	3	14	122	3	14	0.4%	-4.60 [-6.82 , -2.38]	-	
SH (Sarah C. Couch et al.)	122.8	6	81	127	7	81	0.5%	-4.20 [-6.21 , -2.19]	-	
gher fat-DASH diet (Sally Chiu et al.)	125	0.8	36	128.8	0.8	36	14.2%	-3.80 [-4.17 , -3.43]		•••??••
btotal			131			131	15.1%	-3.83 [-4.19 , -3.47]	1	
st for overall effect: Z = 20.95 (P < 0.00001) terogeneity: Chi ² = 0.62, df = 2 (P = 0.73); I ² = 0%										
.6 Unsaturated Fat-Enriched Diets (MUFA/PUFA	-Rich Diets)									
D-Rich in unsaturated fats (Min Wei et al.)	113.5	13.2	38	118	13.4	38	0.1%	-4.50 [-10.48 , 1.48]		
h Intake of unsaturated fat diet (Appel et al.)	121.9	9.3	164	131.2	9.4	164	0.5%	-9.30 [-11.32 , -7.28]	_	
h MUFA intake (Aldo Ferrara et al.)	127	2	14	134	2	17	1.0%	-7.00 [-8.41 , -5.59]	-	
h PUFA intake (Aldo Ferrara et al.)	135	5	13	134	5	17	0.1%	1.00 [-2.61 , 4.61]		
her unsaturated fat diet (Swain et al.)	130.7	5.7	32	146.5	5.7	32	0.2%	-15.80 [-18.59 , -13.01]	-	• • ? • •
tachios with 30% TF; 8% SF (West et al.)	105.7	1.9	28	106.7	1.9	28	2.0%	-1.00 [-2.00 , -0.00]		
btotal			289			296	3.9%	-4.46 [-5.17 , -3.75]	•	
t for overall effect: Z = 12.31 (P < 0.00001) erogeneity: Chi ² = 152.89, df = 5 (P < 0.00001); l ²	= 97%									
7 Low-Fat Diets										
ake of low-fat diet (Straznicky et al.)	122	11	14	131	11	14	0.0%	-9.00 [-17.15 , -0.85]		
ake of low-fat diet (Zhang et al.)	122	13.7	203	120.5	13.9	203	0.0%	-9.50 [-12.18 , -6.82]	_	
v-fat dairy products (Appel et al.)	126.5	5.5	151	132	10.7	203	0.5%	-5.50 [-7.40 , -3.60]	_	
btotal	120.0	0.0	368	152	10.7	371	0.5%	-6.91 [-8.44 , -5.39]	•	
st for overall effect: Z = 8.88 (P < 0.00001)									•	
terogeneity: Chi ² = 5.93, df = 2 (P = 0.05); I ² = 66%	b									
al			14434			14522	100.0%	-2.20 [-2.34 , -2.06]	1	
st for overall effect: Z = 30.94 (P < 0.00001) st for subgroup differences: Chi ² = 273.21, df = 6 (F terogeneity: Chi ² = 970.71, df = 26 (P < 0.00001); I		97.8%						- Favours fatty die	-20 -10 0 10 20 t intervention Favours co	ntrol/normal diet

(A) Random sequence generation (selection bias) (B) Allocation concealment (selection bias)

(C) Blinding of participants and personnel (perfo nance bias)

(D) Blinding of outcome assessment (detection bias)

(E) Incomplete outcome data (attrition bias)

(F) Selective reporting (reporting bias)

(G) Other bias

Figure 2. Effect of various fatty diets on systolic blood pressure (SBP). The graph illustrates the significant reductions in SBP associated with higher intake of unsaturated fats and low-fat diets, compared to the modest effects observed with high-fat and saturated fat diets

(detection bias) (E) Incomplete outcome data (attrition bias) (F) Selective reporting (reporting bias) (G) Other bias domains. Seven studies showed "high risk" and three reveal "unclear risk" in blinding process, probably due to obvious BP readings on display during measurement process. One study manifested "unclear risk" in allocation concealment. The remaining studies showed low risk of bias in remaining parameters.

Publication bias

Visual inspection of the funnel plot (Supplementary Figure 3A & 3B) revealed a generally symmetrical distribution of studies around the mean effect size, suggesting a low likelihood of publication bias. Studies across various dietary interventions-such as high-fat diets, omega-3 fatty acid diets, food-based oil diets, and unsaturated fatenriched diets-are evenly dispersed along both sides of the mean difference (MD) axis. The distribution of studies falls within the expected confidence limits (represented by the dashed lines), indicating no significant asymmetry. This visual assessment was further supported by Egger's test and Begg's test, both of which showed no significant small-study effects for systolic blood pressure (SBP). These findings confirm that the results of this meta-analysis are unlikely to be influenced by publication bias.

	Fat-based dietary intervention		Control group/Standard diet				Mean difference	Mean difference	Risk of Bias	
tudy or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% Cl	IV, Fixed, 95% CI	ABCDEF
2.1 High-Fat Diets										
% fat cheddar cheese-with GABA (Maryka et al.)	80.8	7.7	49	81.2	7.8	53	0.1%	-0.40 [-3.41 , 2.61]	+	
take of high-fat diet (Straznicky et al.)	65	5	14	73	5	14	0.1%	-8.00 [-11.70 , -4.30]		
ubtotal			63			67	0.2%	-3.42 [-5.76 , -1.09]	▲	
est for overall effect: Z = 2.87 (P = 0.004)									•	
eterogeneity: Chi ² = 9.74, df = 1 (P = 0.002); l ² = 90)%									
2.2 Omega-3 Fatty Acid Diets										
axseed oil (Dorien J. Pieters et al.)	88.1	7.6	29	88	7.8	30	0.1%	0.10 [-3.83 , 4.03]	+	
C n-3 PUFA (Kolbrun Sveinsdottir et al.)	74.3	8.3	38	77	8.3	38	0.1%	-2.70 [-6.43 , 1.03]		
C ω-3 fatty acids (EPA & DHA)(Skilton et al.)	56.9	8.3	352	54.1	1	352	1.2%	2.80 [1.93 , 3.67]	-	
mega-3 fatty acid (Chisa Matsumoto et al.)	76.4	6.2	12279	76.3	6.4	12279	36.1%	0.10 [-0.06 , 0.26]	•	
mega-3 fatty acids (Anahita Izadi et al.)	60.92	0.54	60	62.54	0.27	60	38.4%	-1.62 [-1.77 , -1.47]	-	
mega-3-PUFA (Alice V. Stanton et al.)	70.1	10.2	39	74	8.1	42	0.1%	-3.90 [-7.93 , 0.13]		
ubtotal			12797			12801	75.9%	-0.73 [-0.84 , -0.63]		
est for overall effect: Z = 13.24 (P < 0.00001)										
eterogeneity: Chi ² = 303.29, df = 5 (P < 0.00001); l ²	² = 98%									
2.3 Food-Based Oil Diets	77 7	0.2	~~~	70.0	0.0	~~~	0.0%	0.101.0.00.0.00		
oconut Oil-Based HFD (Kay-Tee Khaw. et al.)	77.7	9.3	29	79.8	9.3	29	0.0.0	-2.10 [-6.89 , 2.69]	-	
esame Oil Blend (Sankar Devarajan et al.)	90	6	100	104	5	100		-14.00 [-15.53 , -12.47]	-	
ubtotal			129			129	0.4%	-12.90 [-14.35 , -11.44]	•	
est for overall effect: Z = 17.34 (P < 0.00001) eterogeneity: Chi ² = 21.54, df = 1 (P < 0.00001); l ²	= 95%									
2.4 Saturated Fat Restriction Diets										
duced intake of saturated fats (Lin et al.)	71.6	11.7	140	73.9	10.7	140	0.1%	-2.30 [-4.93 , 0.33]	_	
eplacement diet (SF \rightarrow UFA) (Nupponen et al.)	65.5	7.6	181	66.5	8.3	226	0.4%	-1.00 [-2.55 , 0.55]	_	
estriction of saturated fats (Jula et al.)	88.15	5.85	47	90.15	5.016	44	0.2%	-2.00 [-4.23 , 0.23]	_	
estriction of saturated fats (Niinikoski et al.)	60.5	6.6	248	62.3	7.2	276	0.6%	-1.80 [-2.98 , -0.62]	_	
iturated fat with low PUFA content (Puska et al.)	82	12.8	41	88	12.8	41	0.0%	-6.00 [-11.54 , -0.46]		
ibtotal	02	12.0	657	00	12.0	727	1.4%	-1.74 [-2.56 , -0.93]		
est for overall effect: Z = 4.20 (P < 0.0001) eterogeneity: Chi ² = 3.38, df = 4 (P = 0.50); I ² = 0%								•	· ·	
2.5 DASH Diets (Fat-based variations of the DA	SH Diet)									
ASH (K. E. Harnden et al.)	78.9	2.5	14	82.8	2.5	14	0.3%	-3.90 [-5.75 , -2.05]	-	
ASH (Sarah C. Couch et al.)	76.5	4	81	77.1	5	81	0.5%	-0.60 [-1.99 , 0.79]	1	
igher fat-DASH diet (Sally Chiu et al.)	79	0.5	36	81.2	0.5	36	16.8%	-2.20 [-2.43 , -1.97]		
ubtotal		0.0	131	01.2	0.0	131	17.5%	-2.18 [-2.41 , -1.96]		•••••
est for overall effect: Z = 18.92 (P < 0.00001)									'	
eterogeneity: $Chi^2 = 8.27$, $df = 2$ (P = 0.02); $I^2 = 76$?	%									
2.6 Unsaturated Fat-Enriched Diets (MUFA/PUF/	A-Rich Diets)									
/D-Rich in unsaturated fats (Min Wei et al.)	72.6	8.7	38	75.7	8	38	0.1%	-3.10 [-6.86 , 0.66]		
gh Intake of unsaturated fat diet (Appel et al.)	72.2	8.1	164	77	8.2	164	0.3%	-4.80 [-6.56 , -3.04]	-	
gh MUFA intake (Aldo Ferrara et al.)	84	1.5	8	90	1.5	7	0.4%	-6.00 [-7.52 , -4.48]	-	
igh PUFA intake (Aldo Ferrara et al.)	90	4	8	90	4	7	0.1%	0.00 [-4.06 , 4.06]	+	
istachios with 30% TF; 8% SF (West et al.)	67.8	1	28	67.3	1.2	28	2.7%	0.50 [-0.08 , 1.08]	-	
ubtotal			246			244	3.5%	-0.74 [-1.25 , -0.23]		
est for overall effect: Z = 2.85 (P = 0.004)								• • •	Ĩ	
eterogeneity: Chi ² = 85.54, df = 4 (P < 0.00001); l ²	= 95%									
2.7 Low-Fat Diets	68	5	14	73	F	4.4	0.1%	5 00 [9 70 1 20]		
take of low-fat diet (Straznicky et al.)	68 69.6	5 9.4	14 203		5	14	0.1%	-5.00 [-8.70 , -1.30]	-	
take of low-fat diet (Zhang et al.) ow-fat dairy products (Appel et al.)	82.3	9.4 5	203	75.6 85.3	9.4 4	203 154	0.3%	-6.00 [-7.83 , -4.17] -3.00 [-4.02 , -1.98]	_	
ubtotal	02.3	5	368	00.0	4	371	0.9% 1.2%	-3.00 [-4.02 , -1.96] -3.78 [-4.64 , -2.91]		* * * • • • •
est for overall effect: Z = 8.57 (P < 0.00001)			368			3/1	1.2 /0	0.10 [-4.04 , -2.01]	·	
eterogeneity: $Chi^2 = 8.34$, $df = 2$ (P = 0.02); $I^2 = 76$?	%									
tal			14391			14470	100.0%	-1.09 [-1.19 , -1.00]		
est for overall effect: Z = 22.65 (P < 0.00001)								-	-20 -10 0 10 20	_
est for subgroup differences: Chi ² = 428.02, df = 6 (eterogeneity: Chi ² = 868.13, df = 25 (P < 0.00001);		= 98.6%						Favours fatty diet	Intervention Favours co	ontrol/normal diet
isk of bias legend										
) Random sequence generation (selection bias)										
 Allocation concealment (selection bias) Blinding of participants and personnel (performar 	ce bias)									

(C) Blinding of participants and personnel (performar (D) Blinding of outcome assessment (detection bias)

(E) Incomplete outcome data (attrition bias)

(F) Selective reporting (reporting bias)

(G) Other bias

Figure 3. Effect of various fatty diets on diastolic blood pressure (DBP). The graph highlights the most significant reductions in DBP achieved by high-fat diets, low-fat diets, and saturated fats with low polyunsaturated fatty acid (PUFA) content, with limited effects observed for other dietary interventions

DISCUSSION

The primary objective of this meta-analysis was to quantify the effects of various fatty diet interventions on SBP and DBP. The main findings suggest that higher intake of unsaturated fats and low-fat diets significantly reduces SBP, while diets high in saturated fatty acids, low-fat diets, and saturated fatty acids with low PUFA content are more effective in reducing DBP. This research provides preliminary insights into dietary fat intervention strategies that can help optimize blood pressure control in both hypertensive and normotensive patients. The analysis was based on data from 14,522 participants across 25

trials, encompassing 27 different fatty diet interventions in diverse age groups and populations.

In comparison to previous meta-analyses,47,48 this study extends the understanding of fatty diet associations with BP by analyzing a broader spectrum of dietary interventions. The findings indicate that unsaturated fats and lowfat diets are particularly effective in reducing both SBP and DBP when compared to diets high in SFAs or total fat intake.

Saturated fatty acids have been implicated in influencing BP through several mechanisms. One plausible mechanism is their impact on endothelial function, where SFAs can impair endothelial-dependent vasodilation by

promoting inflammation and oxidative stress, thereby increasing BP.^{49,50} Additionally, SFAs contribute to increased arterial stiffness and elevate circulating low-density lipoprotein (LDL) cholesterol levels, both of which are associated with higher BP.⁵¹ Experimental studies suggest that high-SFA diets can lead to a progressive rise in BP due to increased vascular resistance⁵¹. Moreover, genetic factors such as variants in the fat mass and obesity-associated gene (FTO) may modulate the BP response to saturated fatty acids, with some individuals displaying reduced SBP and DBP regardless of body mass index. Conversely, circulating very-long-chain saturated fatty acids, like arachidic and behenic acids, have been linked to a lower risk of hypertension, illustrating the complexity of SFAs' influence on BP.⁵²

Our analysis demonstrated that restricting saturated fatty acids intake led to modest reductions in SBP and more substantial decreases in DBP. Notably, saturated fatty acids with low PUFA content showed more significant reductions in both SBP and DBP. These results highlight the nuanced effects of different types of saturated fatty acids on BP regulation.

Increased intake of unsaturated fats, particularly PUFAs and monounsaturated fatty acids (MUFAs), demonstrated significant BP-lowering effects.⁵³ PUFAs, especially marine-derived n-3 fatty acids, may lower BP through mechanisms such as improving endothelial function, enhancing nitric oxide production, and exerting antiinflammatory effects.53 Similarly, MUFAs, primarily oleic acid from vegetable oils, have been associated with reductions in DBP, likely due to their favorable effects on lipid profiles and vascular reactivity.54 Our findings support these mechanisms, showing that high intake of unsaturated fats led to the most substantial BP reductions among all dietary interventions analyzed. However, diets high in PUFAs alone showed minimal effects on BP, indicating potential differences in BP-lowering efficacy between n-3 and n-6 fatty acids.55

Low-fat diets, including those resembling the DASH diet, also showed significant BP-lowering effects.^{31,56} These diets likely reduce BP through mechanisms involving improved sodium-potassium balance, enhanced vascular function, and reductions in arterial stiffness.⁵⁷ Our analysis revealed that low-fat diets were effective in lowering SBP and DBP. DASH diets, rich in fruits, vegetables, and low-fat dairy, further supported these findings with modest reductions in both SBP and DBP.

Furthermore, specific dietary interventions such as food-based oil diets (e.g., sesame oil blends) exhibited the most pronounced effects, with reductions in SBP and DBP. These results suggest that targeted dietary modifications, particularly those enriched with bioactive compounds, may offer additional BP-lowering benefits.

In conclusion, this meta-analysis highlights the differential effects of various fatty diet interventions on BP regulation. While unsaturated fat intake demonstrated the most significant benefits, low-fat and certain saturated fatty acids-restricted diets also contributed to BP reduction. The findings underscore the importance of dietary fat composition in hypertension management and provide a foundation for future research to explore the underlying mechanisms and long-term effects of these dietary strategies.

Limitations

The study aimed to include the participants without upper or lower limits of BP that may or may include hypertensive state. This limits the analysis as it is unclear what the data would have implied if only hypertensive patients were included in the analysis. Similarly, age and gender considerations were also not undertaken as the goal of the study was to analyze the effects of fatty diets on BP.

Conclusion

This systematic review and meta-analysis highlight the diverse and nuanced effects of various fatty diets on blood pressure regulation. The findings demonstrate that food-based oil diets, particularly those enriched with sesame oil, and diets high in unsaturated fats produced the most significant reductions in both SBP and DBP. High intake of MUFA and PUFA, as well as omega-3 fatty acid diets, also exhibited notable reductions in SBP and DBP, though to a lesser extent. Low-fat diets and fat-rich adaptations of the DASH diet showed moderate effects in lowering both SBP and DBP. Conversely, diets focused on saturated fat restriction showed minimal impact on blood pressure reduction when compared to control groups. The subgroup analysis underscores the importance of dietary composition in influencing cardiovascular outcomes, particularly highlighting the benefits of unsaturated fat-enriched diets. These findings provide valuable insights that can inform future clinical guidelines and dietary recommendations. Nonetheless, further largescale, long-term trials with diverse dietary interventions are necessary to validate and strengthen these conclusions.

SUPPLEMENTARY MATERIALS

All supplementary tables and figures are available upon request from the editorial office.

CONFLICT OF INTEREST AND FUNDING DISCLO-SURE

The authors declare no competing interests related to this review. The authors have no financial or personal relationships with organizations or individuals that could have influenced the content or outcomes of this work.

No funding was obtained during the preparation of this manuscript.

REFERENCES

- 1. Nestel PJ. Dietary Fat and Blood Pressure. Curr Hypertens Rep. 2019;21:17. doi:10.1007/s11906-019-0918-y
- Djoussé L, Pankow JS, Hunt SC, Heiss G, Province MA, Kabagambe EK, et al. Influence of saturated fat and linolenic acid on the association between intake of dairy products and blood pressure. Hypertension. 2006; 48: 335-41. doi:10.1161/01.HYP.0000229668.73501.e8
- Sacks FM. Dietary fats and blood pressure: a critical review of the evidence. Nutr Rev. Oct 1989;47:291-300. doi:10.1111/j.1753-4887.1989.tb02753.x
- Liu Q. Impact of different dietary fat sources on blood pressure in Chinese adults. PLoS One. 2021;16:e0247116. doi:10.1371/journal.pone.0247116

- DiNicolantonio JJ, J OK. Dietary fats, blood pressure and artery health. Open Heart. 2019;6:e001035. doi:10.1136/openhrt-2019-001035
- Maki KC, Rains TM, Schild AL, Dicklin MR, Park KM, Lawless AL, et al. Effects of low-fat dairy intake on blood pressure, endothelial function, and lipoprotein lipids in subjects with prehypertension or stage 1 hypertension. Vascular health and risk management. 2013;9:369-79. doi:10.2147/vhrm.s45684
- Gou R, Gou Y, Qin J, Luo T, Gou Q, He K, et al. Association of dietary intake of saturated fatty acids with hypertension: 1999-2018 National Health and Nutrition Examination Survey. Frontiers in nutrition. 2022;9:1006247. doi:10.3389/fnut.2022.1006247
- Wang L, Manson JE, Forman JP, Gaziano JM, Buring JE, Sesso HD. Dietary fatty acids and the risk of hypertension in middle-aged and older women. Hypertension (Dallas, Tex : 1979). 2010; 56: 598-604. doi:10.1161/hypertensionaha.110.154187
- Wu MY, Du MH, Wen H, Wang WQ, Tang J, Shen LR. Effects of n-6 PUFA-rich soybean oil, MUFA-rich olive oil and camellia seed oil on weight and cardiometabolic profiles among Chinese women: a 3-month double-blind randomized controlled-feeding trial. Food Funct. 20 2022;13:4375-83. doi:10.1039/d1fo03759e
- Hajihashemi P, Feizi A, Heidari Z, Haghighatdoost F. Association of omega-6 polyunsaturated fatty acids with blood pressure: A systematic review and meta-analysis of observational studies. Crit Rev Food Sci Nutr. 2023;63:2247-59. doi:10.1080/10408398.2021.1973364
- Higgins J, Green S. Cochrane handbook for systematic reviews of interventions (5. IO ed.). Cochrane Book Series. 2011.
- Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Bmj. 2009;339:b2535. doi:10.1136/bmj.b2535
- Higgins J. Cochrane handbook for systematic reviews of interventions. Version 5.1. 0 [updated March 2011]. The Cochrane Collaboration. www cochrane-handbook org. 2011
- Elbourne DR, Altman DG, Higgins JP, Curtin F, Worthington HV, Vail A. Meta-analyses involving crossover trials: methodological issues. Int J Epidemiol. 2002;31:140-9. doi:10.1093/ije/31.1.140
- Paniagua JA, Pérez-Martinez P, Gjelstad IM, Tierney AC, Delgado-Lista J, Defoort C, et al. A low-fat highcarbohydrate diet supplemented with long-chain n-3 PUFA reduces the risk of the metabolic syndrome. Atherosclerosis. 2011;218:443-50. doi: 10.1016/j.atherosclerosis.2011.07.003
- Willis BH, Riley RD. Measuring the statistical validity of summary meta-analysis and meta-regression results for use in clinical practice. Stat Med. 20 2017;36:3283-301. doi:10.1002/sim.7372
- 17. Borenstein M, Hedges LV, Higgins JP, Rothstein HR. Introduction to meta-analysis. Chichester: John wiley & sons; 2021.
- Fonseca BHS, de Andrade PHS, Luvizutto GJ. Does noninvasive brain stimulation improve spatiotemporal gait parameters in people with multiple sclerosis? A systematic review and meta-analysis. J Bodyw Mov Ther. 2024;37:350-9. doi:10.1016/j.jbmt.2023.11.043
- Appel LJ, Sacks FM, Carey VJ, Obarzanek E, Swain JF, Miller ER, et al. Effects of protein, monounsaturated fat, and carbohydrate intake on blood pressure and serum lipids:

results of the OmniHeart randomized trial. Jama. Nov 16 2005;294:2455-64. doi:10.1001/jama.294.19.2455

- 20. Ferrara LA, Raimondi AS, d'Episcopo L, Guida L, Dello Russo A, Marotta T. Olive oil and reduced need for antihypertensive medications. Arch Intern Med. Mar 27 2000;160:837-42. doi:10.1001/archinte.160.6.837
- Harnden KE, Frayn KN, Hodson L. Dietary Approaches to Stop Hypertension (DASH) diet: applicability and acceptability to a UK population. J Hum Nutr Diet. 2010;23:3-10. doi:10.1111/j.1365-277X.2009.01007.x
- 22. Jula A, Rönnemaa T, Rastas M, Karvetti RL, Mäki J. Longterm nopharmacological treatment for mild to moderate hypertension. J Intern Med. 1990;227:413-21. doi:10.1111/j.1365-2796.1990.tb00180.x
- 23. Lin PH, Yancy WS Jr, Pollak KI, Dolor RJ, Marcello J, Samsa GP, et al. The influence of a physician and patient intervention program on dietary intake. J Acad Nutr Diet 2013;113:1465-75. doi:10.1016/j.jand.2013.06.343
- 24. Niinikoski H, Jula A, Viikari J, Rönnemaa T, Heino P, Lagström H, et al. Blood pressure is lower in children and adolescents with a low-saturated-fat diet since infancy: the special turku coronary risk factor intervention project. Hypertension. 2009;53:918-24. doi:10.1161/hypertensionaha.109.130146
- Nupponen M, Pahkala K, Juonala M, Magnussen CG, Niinikoski H, Rönnemaa T, et al. Metabolic syndrome from adolescence to early adulthood: effect of infancy-onset dietary counseling of low saturated fat: the Special Turku Coronary Risk Factor Intervention Project (STRIP). Circulation. 2015;131:605-13. doi:10.1161/circulationaha.114.010532
- 26. Puska P, Iacono JM, Nissinen A, Vartiainen E, Dougherty R, Pietinen P, et al. Dietary fat and blood pressure: an intervention study on the effects of a low-fat diet with two levels of polyunsaturated fat. Preventive medicine. 1985;14:573-84. doi:10.1016/0091-7435(85)90078-7
- Straznicky NE, O'Callaghan CJ, Barrington VE, Louis WJ. Hypotensive effect of low-fat, high-carbohydrate diet can be independent of changes in plasma insulin concentrations. Hypertension. 1999;3:580-5. doi:10.1161/01.hyp.34.4.580
- 28. Swain JF, McCarron PB, Hamilton EF, Sacks FM, Appel LJ. Characteristics of the diet patterns tested in the optimal macronutrient intake trial to prevent heart disease (OmniHeart): options for a heart-healthy diet. J Am Diet Assoc. 2008;108:257-65. doi:10.1016/j.jada.2007.10.040
- ^{29.} West SG, Gebauer SK, Kay CD, Bagshaw DM, Savastano DM, Diefenbach C et al. Diets containing pistachios reduce systolic blood pressure and peripheral vascular responses to stress in adults with dyslipidemia. Hypertension. 2012;60:58-63. doi:10.1161/hypertensionaha.111.182147
- 30. Zhang X, Qi Q, Liang J, Hu FB, Sacks FM, Qi L. Neuropeptide Y promoter polymorphism modifies effects of a weight-loss diet on 2-year changes of blood pressure: the preventing overweight using novel dietary strategies trial. Hypertension. 2012;60:1169-75. doi:10.1161/hypertensionaha.112.197855
- 31. Appel LJ, Moore TJ, Obarzanek E, et al. A clinical trial of the effects of dietary patterns on blood pressure. DASH Collaborative Research Group. N Engl J Med 1997;336:1117-24. doi:10.1056/nejm199704173361601
- 32. Rancourt-Bouchard M, Gigleux I, Guay V, Charest A, Saint-Gelais D, Vuillemard JC, et al. Effects of regular-fat and low-fat dairy consumption on daytime ambulatory blood pressure and other cardiometabolic risk factors: a randomized controlled feeding trial. Am J Clin Nutr 2020;111:42-51. doi:10.1093/ajcn/nqz251

- 33. Chiu S, Bergeron N, Williams PT, Bray GA, Sutherland B, Krauss RM. Comparison of the DASH (Dietary Approaches to Stop Hypertension) diet and a higher-fat DASH diet on blood pressure and lipids and lipoproteins: a randomized controlled trial. The Am J Clin Nutr2016;103:341-7. doi:10.3945/ajcn.115.123281
- 34. Couch SC, Saelens BE, Khoury PR, Dart KB, Hinn K, Mitsnefes MM, et al. Dietary Approaches to Stop Hypertension Dietary Intervention Improves Blood Pressure and Vascular Health in Youth With Elevated Blood Pressure. Hypertension. 2021;77:241-51. doi:10.1161/hypertensionaha.120.16156
- 35. Stanton AV, James K, Brennan MM, O'Donovan F, Buskandar F, Shortall K, et al. Omega-3 index and blood pressure responses to eating foods naturally enriched with omega-3 polyunsaturated fatty acids: a randomized controlled trial. Sci Rep. 2020;10:15444. doi:10.1038/s41598-020-71801-5
- 36. Izadi A, Khedmat L, Tavakolizadeh R, Mojtahedi SY. The intake assessment of diverse dietary patterns on childhood hypertension: alleviating the blood pressure and lipidemic factors with low-sodium seafood rich in omega-3 fatty acids. Lipids Health Dis 2020;19:65. doi:10.1186/s12944-020-01245-3
- Matsumoto C, Yoruk A, Wang L, Gaziano JM, Sesso HD. Fish and omega-3 fatty acid consumption and risk of hypertension. J Hypertens. 2019;37:1223-9. doi:10.1097/hjh.00000000002062
- 38. Devarajan S, Singh R, Chatterjee B, Zhang B, Ali A. A blend of sesame oil and rice bran oil lowers blood pressure and improves the lipid profile in mild-to-moderate hypertensive patients. J Clin Lipidol2016;10:339-49. doi:10.1016/j.jacl.2015.12.011
- 39. Pieters DJ, Zock PL, Fuchs D, Mensink RP. Effect of αlinolenic acid on 24-h ambulatory blood pressure in untreated high-normal and stage I hypertensive subjects. The Br J Nutr. 2019;121:155-63. doi:10.1017/s00071145180030 94
- 40. Khaw KT, Sharp SJ, Finikarides L, Afzal I, Lentjes M, Luben R, et al. Randomised trial of coconut oil, olive oil or butter on blood lipids and other cardiovascular risk factors in healthy men and women. BMJ open. 2018;8:e020167. doi:10.1136/bmjopen-2017-020167
- 41. Sveinsdottir K, Martinsdottir E, Ramel A. Blood pressurelowering effects of long chain n-3 fatty acids from meals enriched with liquid fish oil and from microencapsulated powder. Int J Food Sci Nutr. 2016;67:1017-23. doi:10.1080/09637486.2016.1208733
- 42. Wei M, Brandhorst S, Shelehchi M, Mirzaei H, Cheng CW, Budniak J, et al. Fasting-mimicking diet and markers/risk factors for aging, diabetes, cancer, and cardiovascular disease. Science translational medicine. 2017;9. doi:10.1126/scitranslmed.aai8700
- 43. Skilton MR, Raitakari OT, Celermajer DS. High intake of dietary long-chain ω-3 fatty acids is associated with lower blood pressure in children born with low birth weight: NHANES 2003-2008. Hypertension. 2013;61:972-6. doi:10.1161/hypertensionaha.111.01030
- 44. Ferrara AL, Pacioni D, Di Fronzo V, Russo BF, Staiano L, Speranza E, et al. Lifestyle educational program strongly increases compliance to nonpharmacologic intervention in

hypertensive patients: a 2-year follow-up study. J Clin Hypertens. 2012;14:767-72. doi:10.1111/jch.12016

- 45. Couch SC, Saelens BE, Levin L, Dart K, Falciglia G, Daniels SR. The efficacy of a clinic-based behavioral nutrition intervention emphasizing a DASH-type diet for adolescents with elevated blood pressure. J Pediatr 2008;152:494-501. doi:10.1016/j.jpeds.2007.09.022
- 46. Matsumoto C, Hanson NQ, Tsai MY, Glynn RJ, Gaziano JM, Djoussé L. Plasma phospholipid saturated fatty acids and heart failure risk in the Physicians' Health Study. Clin Nutr. 2013;32:819-23. doi:10.1016/j.clnu.2013.02.006
- 47. Gay HC, Rao SG, Vaccarino V, Ali MK. Effects of different dietary interventions on blood pressure: systematic review and meta-analysis of randomized controlled trials. Hypertension. 2016;67:733-9. doi: 10.1161/HYPERTENSI ONAHA.115.06853
- 48. Yang Q, Lang X, Li W, Liang Y. The effects of low-fat, high-carbohydrate diets vs. low-carbohydrate, high-fat diets on weight, blood pressure, serum liquids and blood glucose: a systematic review and meta-analysis. Eur J Clin Nutr 2022;76:16-27. doi: 10.1038/s41430-021-00927-0
- 49. Stanek A, Grygiel-Górniak B, Brożyna-Tkaczyk K, Myśliński W, Cholewka A, Zolghadri S. The influence of dietary interventions on arterial stiffness in overweight and obese subjects. Nutrients. 2023;15:1440. doi: 10.3390/nu15061440.
- Mallick R, Duttaroy AK. Modulation of endothelium function by fatty acids. Mol Cell Biochem. 2022;477:15-38. doi: 10.1007/s11010-021-04260-9
- 51. Grimsgaard S, Bønaa KH, Jacobsen BK, Bjerve KS. Plasma saturated and linoleic fatty acids are independently associated with blood pressure. Hypertension. 1999;34:478-83. doi: 10.1161/01.HYP.34.3.478
- 52. Bockus LB, Biggs ML, Lai HTM, de Olivera Otto MC, Fretts AM, McKnight B, et al. Assessment of plasma phospholipid very-long-chain saturated fatty acid levels and healthy aging. JAMA network open. 2021;4:e2120616e2120616. doi: 10.1001/jamanetworkopen.2021.20616.
- 53. Zehr KR, Walker MK. Omega-3 polyunsaturated fatty acids improve endothelial function in humans at risk for atherosclerosis: A review. Prostaglandins Other Lipid Mediat. 2018;134:131-40. doi:10.1016/j.prostaglandins.2017.07. 005
- 54. Miura K, Stamler J, Brown IJ, Ueshima H, Nakagawa H, Sakurai M, et al. Relationship of dietary monounsaturated fatty acids to blood pressure: the International Study of Macro/Micronutrients and Blood Pressure. J Hypertens. 2013;31:1144-50. doi:10.1097/HJH.0b013e3283604016
- 55. James JD, James O. Dietary fats, blood pressure and artery health. Open Heart. 2019;6:e001035. doi:10.1136/openhrt-2019-001035
- 56. Foraker RE, Pennell M, Sprangers P, Vitolins MZ, DeGraffinreid C, Paskett ED. Effect of a low-fat or lowcarbohydrate weight-loss diet on markers of cardiovascular risk among premenopausal women: a randomized trial. J Womens Health. 2014;23:675-80. doi:10.1089/jwh.2013.46 38
- 57. Salahou MO. Preventing and Managing Hypertension with a Dash Diet Eating Plan. Phoenix, AZ: Grand Canyon University; 2021.